Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ADVANCE-CIDP 3

Celgene building

Myeloma market set to be $9bn by 2021

New research shows it will pushed by a growing prevalence of the disease

- PMLiVE

US filing aims to elevate Brintellix above its competition

Drug looking for an edge in the highly competitive major depressive disorder market

RRD International hires Ulrich Thienel as CDMO

Company expands leadership team with former Takeda VP

- PMLiVE

Takeda files ‘oral Velcade’ for myeloma in US

Follow up could be the first pill approved for this rare cancer

- PMLiVE

Adam Zaeske appointed as new MD of Takeda UK

Promoted after 11 years with the company

- PMLiVE

Baxalta will add $2.5bn in new product turnover by 2020

Pro forma sales expected to grow up to 8% between 2016 and 2020

UK flag

London life science growth boosted by Takeda

Japanese firm adds to recent surge in pharma spending in the capital

- PMLiVE

Takeda strengthens leadership team with business unit director

Craig Adkins takes up the position after being at the firm for ten years

- PMLiVE

Takeda to pay $2.4bn to settle Actos cancer suits

Will be one of the largest drug safety settlements in US history

- PMLiVE

AZ and Takeda drugs should carry heart failure warning

FDA panel claim diabetes drugs Onglyza and Nesina need label updates

- PMLiVE

Takeda’s once-weekly DPP-4 inhibitor cleared in first market

Zafatek’s authorisation one of a flurry of new approvals for a number of firms in Japan

- PMLiVE

Takeda spends $230m on oncology biotech deal

Buys into ImmunoGen’s antibody-drug conjugate technology

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links